Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01101750 · ClinicalTrials.gov registry record · Phase 4

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

A Phase 4 study, sponsored by Medstar Health Research Institute.

Completed
Registry status
Phase 4
Development phase
25
Enrollment target

NCT01101750: Completed Phase 4 study, sponsored by Medstar Health Research Institute.

NCT01101750 is a Phase 4 study that has completed, run by Medstar Health Research Institute. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01101750, a Phase 4 study, has completed, sponsored by Medstar Health Research Institute.

COMPLETED
Registry status
Phase 4
Development phase
25 participants
Enrollment target

Study Summary

The purpose of the study is to understand if children with liver and kidney transplants develop the antibodies from the Gardasil vaccine. The Gardasil vaccine protects against Human Papilloma Virus (HPV) types 16 and 18, which cause most types of cancers of the cervix, vagina and vulva. It also protects against Human Papilloma Virus types 6 and 11, which cause genital warts in some people. Gardasil has been approved by the Food and Drug Administration and is recommended for girls and women from ages 9-26 for the prevention of some types of cancer of the cervix, vagina and vulva as well as preventing some types of genital warts. In males that are 9-26 years old, the FDA has approved its use for prevention of some types of genital warts. The Gardasil vaccine is made from a virus like particle and does not contain any live virus. Children with an allergy to yeast should not receive the vaccine since some components of the vaccine are made from yeast. People who have undergone organ transplant are at increased risk of of developing genital warts and cancers related to HPV when compared to the general population. The American Society of Transplantation and the American Society of Transplant Surgeons recommend the vaccine for people with transplants. Studies of other vaccines like Hepatitis B have shown children after transplant have less of a response to this vaccine and are not immune to the Hepatitis B virus. We are interested in seeing if your child will form antibodies (immune response) to the Gardasil vaccine. Your child is being asked to be in the study because he or she is between the ages of 9-17 and has undergone a liver or kidney transplant more than 6 months ago and does not have any signs of organ rejection.

Interventions

  • BIOLOGICAL Quadrivalent HPV for types 6, 11, 16 and 18

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2010-05
Est. Completion 2012-12-14
Phase Phase 4
Medstar Health Research Institute

115 total trials

What the finished NCT01101750 record still lists

NCT01101750 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which Quadrivalent HPV for types 6, 11, 16 and 18 is the first listed.

NCT01101750 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01101750 about?

NCT01101750 is a clinical study titled "Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?". The purpose of the study is to understand if children with liver and kidney transplants develop the antibodies from the Gardasil vaccine. The Gardasil vaccine protects against Human Papilloma Virus (HPV) types 16 and 18, which cause most types of cancers of the cervix, vagina and vulva. It also pro...

What is the current status of trial NCT01101750?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2010-05. Estimated completion is 2012-12-14.

What interventions are being tested in trial NCT01101750?

The interventions under investigation include: Quadrivalent HPV for types 6, 11, 16 and 18 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01101750?

This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01101750's enrollment target sits among peer trials

25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01101750, the US trial registry maintained by the National Library of Medicine. NCT01101750 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.